CTNM

Contineum is a clinical-stage biopharma with no approved products, no recurring revenue, and value that rests entirely on early-stage clinical readouts. The FY2023 'revenue' of $50.0M was a one-off (the Feb-2023 J&J upfront for PIPE-307); revenue fell to $0.00 in FY2024 and is absent in FY2025, so there is no commercial business to underwrite. Losses are widening — net income -$60.0M (from -$42.3M) and operating income -$68.1M — with R&D up 34.1% to $51.5M and operating cash burn of -$55.3M. This is a cash-incinerating story where the only question is whether the science works, and the provided data cannot answer that.

The balance sheet is the one genuine strength and the reason this is 'avoid' rather than a screaming short: liabilities are just $15.7M against $261M equity (0.06x), current assets of $268M dwarf $9.74M current liabilities, and cash rose 244.5% to $75.6M. That funds several years of runway. But the filing shows the value proposition just took a real hit: the November 2025 VISTA Phase 2 trial of PIPE-307 in RRMS 'did not meet its prespecified primary and secondary efficacy endpoints,' and J&J holds 'sole discretion whether or not to further develop PIPE-307' — so the partnered leg of the pipeline is now in doubt and outside the company's control.